| Name | Title | Contact Details |
|---|---|---|
Yuhong Qiu |
VP, Regulatory Affairs | Profile |
Jim Pepin |
General Counsel | Profile |
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Our lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials in solid tumor and hematologic indications. Our pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 dose-escalation trial, and KO-539, a menin-MLL inhibitor, currently in preclinical development.
Newlight Technologies is a company based in Irvine, California known for carbon sequestration into plastics.
Swing Therapeutics was founded in 2019 with the goal of developing digital treatments in disease areas where patients are not well-served, and where digital interventions may be effective.
Sequenom is a leading high-performance DNA analysis company organized into two distinct business units:Sequenom Genetic Systems and Sequenom Pharmaceuticals.
Bioforward is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.